ESSA Bancorp, Inc.

    ESSA Bancorp, Inc.

    NNASDAQ:ESSA
    - -
    USD
    - -
    - -
    12.15P/E
    2012 Y
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    3.24
    4.14
    4.37
    4.94
    5.36
    5.07
    5.17
    5.14
    5.94
    6.47
    6.99
    7.14
    6.97
    6.87
    Basic EPS, GAAP
    0.02
    0.76
    0.79
    0.94
    0.74
    0.69
    0.6
    1.18
    1.39
    1.65
    2.06
    1.91
    1.78
    1.55
    Free Cash Flow per Basic Share
    0.41
    1.94
    1.27
    1.77
    1.64
    1.78
    2.16
    1.62
    1.81
    1.91
    2.27
    2.05
    1.39
    1.35
    Dividend per Share
    0.2
    0.2
    0.26
    0.34
    0.36
    0.36
    0.36
    0.4
    0.44
    0.47
    0.54
    0.6
    0.62
    0.62
    Book Value per Share
    5.91
    6.22
    7.17
    8.02
    8.45
    8.61
    8.7
    9.56
    10.9
    12.52
    14.27
    15.63
    17.17
    17.57
    Tangible Book Value per Share
    14.79
    13.42
    14.3
    15.23
    15.39
    15.76
    15.14
    16.27
    17.09
    18.85
    20.31
    21.16
    22.72
    23.37
    Basic Weighted Avg Shares
    11
    12
    11
    10
    10
    11
    11
    11
    10
    10
    10
    10
    10
    10
    Sales/Revenue/Turnover
    36
    48
    47
    52
    56
    54
    56
    55
    61
    64
    68
    69
    66
    65
    Operating Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Depreciation Expense
    1
    2
    2
    2
    2
    2
    2
    1
    2
    2
    2
    2
    2
    2
    Net Income, GAAP
    - -
    9
    9
    10
    8
    7
    7
    13
    14
    16
    20
    19
    17
    15
    Effective Tax Rate (%)
    13.31
    24.31
    25.37
    23.18
    25.05
    17.82
    46.45
    16.06
    18.09
    17.45
    19.73
    19.48
    18.94
    19.19
    Profit Margin (%)
    0.6
    18.43
    17.97
    18.94
    13.87
    13.66
    11.65
    22.88
    23.46
    25.51
    29.39
    26.74
    25.56
    22.59
    Working Capital
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    LT Debt
    191
    119
    151
    229
    231
    174
    119
    141
    14
    - -
    - -
    - -
    10
    - -
    Total Equity
    175
    166
    167
    171
    176
    183
    179
    190
    191
    202
    212
    220
    230
    236
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    0.32
    12.86
    11.38
    12.13
    9
    8.19
    7.04
    12.82
    13.38
    13.84
    15.21
    12.75
    10.76
    9.07

    Capital Structure

    USD

    •

    in mil. unless spec.
    Sep'24
    Dec'25
    Mar'25
    ST Debt
    280
    215
    201
    LT Borrowings
    10
    10
    - -
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    10
    10
    10
    Market Capitalization
    182
    186
    180

    Working Capital

    USD

    •

    in mil. unless spec.
    Sep'24
    Dec'25
    Mar'25
    Total Current Assets
    - -
    - -
    - -
    Cash, Cash Equivalents & STI
    264
    62
    36
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    - -
    - -
    - -
    Payables & Accruals
    - -
    - -
    - -
    ST Debt
    280
    215
    201
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    3.28%
    4%
    4.88%
    Free Cash Flow
    1.72%
    -3.58%
    -33.65%
    Net Income, GAAP
    10.57%
    6.87%
    -8.53%
    Sales/Revenue/Turnover
    3.59%
    3.93%
    -4.29%
    Total Cash Common Dividend
    7.98%
    6.81%
    0.79%

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    18
    17
    17
    18
    69
    2024
    17
    17
    16
    17
    66
    2025
    16
    16
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    0.5
    0.48
    0.45
    0.47
    1.91
    2024
    0.45
    0.48
    0.41
    0.44
    1.78
    2025
    0.41
    0.29
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    0.15
    0.15
    0.15
    0.15
    0.6
    2024
    0.15
    0.16
    0.16
    0.16
    0.62
    2025
    0.15
    0.15
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • prnewswire.com

      ESSA Announces Completion of Arrangement with XenoTherapeutics

    • prnewswire.com

      ESSA Securityholders Approve Acquisition by XenoTherapeutics

    • prnewswire.com

      ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order

    • globenewswire.com

      K12 Tutoring Strengthens ESSA Validation with New Multi-Grade Results

    • prnewswire.com

      ESSA Pharma Inc. Amends Agreement with XenoTherapeutics

    • globenewswire.com

      CNB Financial Corporation Completes Merger with ESSA Bancorp, Inc.

    • prnewswire.com

      ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to Shareholders

    • prnewswire.com

      ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

    • accessnewswire.com

      CNB Financial Corporation and ESSA Bancorp, Inc. Receive Bank Regulatory Approvals for Merger

    • globenewswire.com

      CNB Financial Corporation and ESSA Bancorp, Inc. Receive Bank Regulatory Approvals for Merger

    • accessnewswire.com

      ESSA Bancorp, Inc. Declares Quarterly Dividend

    • prnewswire.com

      ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025

    • globenewswire.com

      K12 Tutoring Earns ESSA Level II Validation, Confirming Impact on Student Achievement

    • accessnewswire.com

      ESSA Bancorp, Inc. Announces Fiscal Second Quarter and Fiscal First Half 2025 Financial Results

    • globenewswire.com

      CNB Financial Corporation Announces that ISS Recommends Shareholders Support the Proposal to Issue Common Stock in connection with the Merger with ESSA Bancorp, Inc., the Proposal to Approve the 2025 Omnibus Incentive Plan and the Say-on-Pay Proposal

    • accessnewswire.com

      Shareholders of ESSA Pharma Inc. Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX

    • prnewswire.com

      ESSA Pharma Inc. Class Action: Levi & Korsinsky Reminds ESSA Pharma Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 25, 2025 - EPIX

    • accessnewswire.com

      ESSA Pharma Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - EPIX

    • accessnewswire.com

      ESSA Pharma Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – EPIX

    • globenewswire.com

      ESSA Pharma Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion